New drug duo shows promise for slowing lymphoma
NCT ID NCT03789240
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests whether combining copanlisib and rituximab can slow the growth of follicular lymphoma, a type of blood cancer. About 33 adults with untreated follicular lymphoma will receive the drugs through an IV over several 28-day cycles. The goal is to see how many patients achieve a complete response, meaning no signs of cancer on scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.